Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ON Semiconductor (ON) vs TG Therapeutics Inc (TGTX) Price & Performance

ON SemiconductorTrade
TG Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

ON Semiconductor vs TG Therapeutics Inc — how do they compare? ON Semiconductor trades at $76.9 (market cap $30.92B), while TG Therapeutics Inc trades at $54.88 (market cap $8.16B). The key difference: ON Semiconductor is far larger — about 3.8× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, ON Semiconductor nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold ON Semiconductor for 5 Days and TG Therapeutics Inc for 16 Days on average.

ONTGTX
Market Cap
$30.92B$8.16B
Volume
11,639,0371,735,121
Sector
TechnologyHealth
52-Week High
$133.93$59.06
52-Week Low
$44.90$26.94
Typical Hold Time
5 Days16 Days
Enterprise Value
$31.53B$8.37B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ON Semiconductor

No Aura AI signal available yet.

TG Therapeutics Inc

TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.

The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

ON
48% Buy52% Sell
Avg holding period · 5 Days
TGTX
0% Buy100% Sell
Avg holding period · 16 Days

Top news

Latest headlines on both assets

About ON Semiconductor

Onsemi develops power and sensing semiconductors for automotive, industrial, and energy applications. Its products support functions such as electric vehicle systems, energy conversion, automation, and intelligent sensing.

Read more on ON →

About TG Therapeutics Inc

TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.

Read more on TGTX →